ELI LILLY & Co — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that ELI LILLY & Co filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $65.18B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $45.04B | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $34.12B | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $28.54B | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $28.32B | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | $24.54B | Feb 22, 2023 |
| FY2019 | Dec 31, 2019 | $6.11B | Feb 19, 2020 |
| FY2019 | Sep 30, 2019 | $5.48B | Feb 19, 2020 |
| FY2019 | Jun 30, 2019 | $5.64B | Feb 19, 2020 |
| FY2019 | Mar 31, 2019 | $5.09B | Feb 19, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $20.64B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $10.59B | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $5.24B | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $6.24B | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $5.58B | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | $6.19B | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $8.32B | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | $3.23B | Feb 17, 2021 |
| FY2019 | Dec 31, 2017 | ($204.10M) | Feb 19, 2020 |
| FY2016 | Dec 31, 2016 | $771.80M | Feb 21, 2017 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $7.19B | Feb 22, 2023 |
| FY2022 | Dec 31, 2021 | $6.93B | Feb 22, 2023 |
| FY2022 | Dec 31, 2020 | $5.98B | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $5.60B | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | $5.05B | Feb 17, 2021 |
| FY2019 | Dec 31, 2017 | $5.10B | Feb 19, 2020 |
| FY2018 | Dec 31, 2016 | $5.31B | Feb 19, 2019 |
| FY2017 | Dec 31, 2015 | $4.80B | Feb 20, 2018 |
| FY2016 | Dec 31, 2014 | $4.73B | Feb 21, 2017 |
| FY2015 | Dec 31, 2013 | $5.53B | Feb 19, 2016 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.09B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $8.59B | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $7.40B | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $6.44B | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $6.43B | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | $6.12B | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $6.21B | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | $5.98B | Feb 17, 2021 |
| FY2019 | Dec 31, 2017 | $5.98B | Feb 19, 2020 |
| FY2018 | Dec 31, 2016 | $6.53B | Feb 19, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $16.81B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $8.82B | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $4.24B | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $7.59B | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $7.37B | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | $6.50B | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $4.84B | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | $5.52B | Feb 17, 2021 |
| FY2019 | Dec 31, 2017 | $5.62B | Feb 19, 2020 |
| FY2018 | Dec 31, 2016 | $4.85B | Feb 19, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $112.48B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $78.72B | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | $64.01B | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | $49.49B | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | $48.81B | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | $46.63B | Feb 23, 2022 |
| FY2020 | Dec 31, 2019 | $39.29B | Feb 17, 2021 |
| FY2019 | Dec 31, 2018 | $43.91B | Feb 19, 2020 |
| FY2018 | Dec 31, 2017 | $44.98B | Feb 19, 2019 |
| FY2017 | Dec 31, 2016 | $38.81B | Feb 20, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $26.54B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $14.27B | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | $10.77B | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | $10.65B | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | $8.98B | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | $5.64B | Feb 23, 2022 |
| FY2020 | Dec 31, 2019 | $2.61B | Feb 17, 2021 |
| FY2019 | Dec 31, 2018 | $9.83B | Feb 19, 2020 |
| FY2018 | Dec 31, 2017 | $11.59B | Feb 19, 2019 |
| FY2017 | Dec 31, 2016 | $14.01B | Feb 20, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.90B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $5.77B | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | $4.94B | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | $4.07B | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | $3.89B | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | $3.77B | Feb 23, 2022 |
| FY2020 | Dec 31, 2019 | $3.68B | Feb 17, 2021 |
| FY2019 | Dec 31, 2018 | $1.37B | Feb 19, 2020 |
| FY2018 | Dec 31, 2017 | $4.37B | Feb 19, 2019 |
| FY2017 | Dec 31, 2016 | $3.97B | Feb 20, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $24.47B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $13.55B | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | $10.31B | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | $10.04B | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | $8.96B | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | $7.83B | Feb 23, 2022 |
| FY2020 | Dec 31, 2019 | $4.92B | Feb 17, 2021 |
| FY2019 | Dec 31, 2018 | $11.40B | Feb 19, 2020 |
| FY2018 | Dec 31, 2017 | $13.89B | Feb 19, 2019 |
| FY2017 | Dec 31, 2016 | $16.05B | Feb 20, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.27B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $3.27B | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | $2.82B | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | $2.07B | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | $3.82B | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | $3.66B | Feb 23, 2022 |
| FY2020 | Dec 31, 2019 | $2.34B | Feb 17, 2021 |
| FY2019 | Dec 31, 2018 | $7.32B | Feb 19, 2020 |
| FY2018 | Dec 31, 2017 | $6.54B | Feb 19, 2019 |
| FY2018 | Dec 31, 2016 | $4.58B | Feb 19, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $29.47B | Feb 19, 2025 |
| FY2024 | Dec 31, 2023 | $19.10B | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | $14.82B | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | $16.74B | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | $16.35B | Feb 23, 2022 |
| FY2020 | Dec 31, 2019 | $13.64B | Feb 17, 2021 |
| FY2016 | Dec 31, 2016 | $9.01B | Feb 21, 2017 |
| FY2016 | Dec 31, 2015 | $7.98B | Feb 21, 2017 |
| FY2013 | Dec 31, 2013 | $5.21B | Feb 19, 2014 |
| FY2013 | Dec 31, 2012 | $5.53B | Feb 19, 2014 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 23 | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | 11 | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | 5 | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | 6 | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | 6 | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | 6 | Feb 22, 2023 |
| FY2019 | Dec 31, 2019 | 1 | Feb 19, 2020 |
| FY2019 | Sep 30, 2019 | 1 | Feb 19, 2020 |
| FY2019 | Jun 30, 2019 | 1 | Feb 19, 2020 |
| FY2019 | Mar 31, 2019 | 4 | Feb 19, 2020 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 22 | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | 11 | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | 5 | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | 6 | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | 6 | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | 6 | Feb 22, 2023 |
| FY2019 | Dec 31, 2019 | 1 | Feb 19, 2020 |
| FY2019 | Sep 30, 2019 | 1 | Feb 19, 2020 |
| FY2019 | Jun 30, 2019 | 1 | Feb 19, 2020 |
| FY2019 | Mar 31, 2019 | 4 | Feb 19, 2020 |